U.S. markets open in 3 hours 52 minutes
  • S&P Futures

    3,792.50
    -24.25 (-0.64%)
     
  • Dow Futures

    31,083.00
    -153.00 (-0.49%)
     
  • Nasdaq Futures

    12,595.25
    -86.50 (-0.68%)
     
  • Russell 2000 Futures

    2,181.30
    -24.50 (-1.11%)
     
  • Crude Oil

    60.66
    -0.62 (-1.01%)
     
  • Gold

    1,707.20
    -8.60 (-0.50%)
     
  • Silver

    25.89
    -0.50 (-1.88%)
     
  • EUR/USD

    1.2042
    -0.0025 (-0.20%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.42
    +3.32 (+13.78%)
     
  • GBP/USD

    1.3935
    -0.0018 (-0.13%)
     
  • USD/JPY

    107.3300
    +0.3280 (+0.31%)
     
  • BTC-USD

    49,180.05
    -2,020.97 (-3.95%)
     
  • CMC Crypto 200

    986.56
    -0.65 (-0.07%)
     
  • FTSE 100

    6,583.21
    -92.26 (-1.38%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET.

A live webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005130/en/

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com